We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Pfizer, BP, Fidelity National Information Services, Deere & Company and Equity Residential
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 2, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , BP p.l.c. (BP - Free Report) , Fidelity National Information Services (FIS - Free Report) , Deere & Company (DE - Free Report) and Equity Residential (EQR - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Pfizer, BP and Fidelity National Information Services
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, BP p.l.c. and Fidelity National Information Services. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Pfizer’s shares have underperformed the Zacks Large-Cap Pharmaceuticals industry over the past year (-6.8% vs. +14.8%). The Zacks analyst believes that the Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. The company expects continued strong growth of key brands like Ibrance, Xeljanz and Eliquis to drive sales in the coming quarters. Pfizer is also strengthening its pipeline and hopes to launch new innovative medicines in the next five years, which can drive long-term growth.
However, Lyrica generic erosion, currency headwinds and pricing pressure are key near-term, top-line headwinds. Estimates have remained stable ahead of Q4 earnings release. Pfizer has a positive record of earnings surprises in the recent quarters.
Shares of BP have gained +3.7% in the past three months against the Zacks International Integrated Oil industry’s rise of +4.6%. The Zacks analyst believes that BP has been benefiting from a strong portfolio of upstream projects. Since 2016, the British energy giant has placed 23 major upstream projects online.
All the key projects BP has been delivering over the years backed the company to post record production levels. These projects will also help the firm boost production by 900 Mboe/d within 2021. Moreover, BP plans to boost spending on renewable power business as most European firms have decided to combat climate change.
However, the 2010 oil-spill incident in the BP-operated Macondo Prospect is still affecting the company. Although it cleared the huge litigation expenses related to the spill, it had to divest some of its best operating properties. Also, the company expects refining margins in the December quarter of 2019 to drop sequentially due to continued turnaround activities.
Fidelity National Information Services' shares have gained +9.8% over the past six months against the Zacks Financial Transaction Services industry's rise of +5.5%. The Zacks analyst believes that the company remains well positioned for growth backed by its attractive core business with a recurring revenue model, digitization, and several ongoing strategic initiatives.
Fidelity’s deal to acquire Worldpay is likely to accelerate its growth by boosting presence in faster growing markets. Also, the transaction will provide synergies of $700 million from revenue and cost management over next three years. However, the company remains exposed to consolidation in the banking sector and significant competition from new entrants. Also, unsustainable capital deployment activities of the company remain a concern.
Other noteworthy reports we are featuring today include Deere & Company and Equity Residential.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Pfizer, BP, Fidelity National Information Services, Deere & Company and Equity Residential
For Immediate Release
Chicago, IL – January 2, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , BP p.l.c. (BP - Free Report) , Fidelity National Information Services (FIS - Free Report) , Deere & Company (DE - Free Report) and Equity Residential (EQR - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Pfizer, BP and Fidelity National Information Services
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, BP p.l.c. and Fidelity National Information Services. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Pfizer’s shares have underperformed the Zacks Large-Cap Pharmaceuticals industry over the past year (-6.8% vs. +14.8%). The Zacks analyst believes that the Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. The company expects continued strong growth of key brands like Ibrance, Xeljanz and Eliquis to drive sales in the coming quarters. Pfizer is also strengthening its pipeline and hopes to launch new innovative medicines in the next five years, which can drive long-term growth.
However, Lyrica generic erosion, currency headwinds and pricing pressure are key near-term, top-line headwinds. Estimates have remained stable ahead of Q4 earnings release. Pfizer has a positive record of earnings surprises in the recent quarters.
Shares of BP have gained +3.7% in the past three months against the Zacks International Integrated Oil industry’s rise of +4.6%. The Zacks analyst believes that BP has been benefiting from a strong portfolio of upstream projects. Since 2016, the British energy giant has placed 23 major upstream projects online.
All the key projects BP has been delivering over the years backed the company to post record production levels. These projects will also help the firm boost production by 900 Mboe/d within 2021. Moreover, BP plans to boost spending on renewable power business as most European firms have decided to combat climate change.
However, the 2010 oil-spill incident in the BP-operated Macondo Prospect is still affecting the company. Although it cleared the huge litigation expenses related to the spill, it had to divest some of its best operating properties. Also, the company expects refining margins in the December quarter of 2019 to drop sequentially due to continued turnaround activities.
Fidelity National Information Services' shares have gained +9.8% over the past six months against the Zacks Financial Transaction Services industry's rise of +5.5%. The Zacks analyst believes that the company remains well positioned for growth backed by its attractive core business with a recurring revenue model, digitization, and several ongoing strategic initiatives.
Fidelity’s deal to acquire Worldpay is likely to accelerate its growth by boosting presence in faster growing markets. Also, the transaction will provide synergies of $700 million from revenue and cost management over next three years. However, the company remains exposed to consolidation in the banking sector and significant competition from new entrants. Also, unsustainable capital deployment activities of the company remain a concern.
Other noteworthy reports we are featuring today include Deere & Company and Equity Residential.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.